This issue of DIAGNOSTIC IMAGING SCAN is number 120, marking fivefull years of publication. It has been a wild and fun five yearsfor us. Few industries other than medical imaging could offerso much corporate drama and technological razzmatazz.SCAN's
This issue of DIAGNOSTIC IMAGING SCAN is number 120, marking fivefull years of publication. It has been a wild and fun five yearsfor us. Few industries other than medical imaging could offerso much corporate drama and technological razzmatazz.
SCAN's prime objective has been and always will be to provideuseful information and industry insights before they become commonknowledge. We hope this newsletter has accomplished that goalmore often than not.
Plans for the future include increased coverage of the hospitalcustomer and group purchasing trends for both medical imagingequipment and services. Our phone and fax lines are always openfor comments, tips and general discussion. Keep in touch.
SCAN started publishing on July 8, 1987. We were lucky to havehad a scoop for our first front page. Frank Hopkins of North AmericanPhilips had been tagged to head up the company that was to beformed through the proposed merger of Picker International andPhilips Medical Systems. We affectionately called the nascentventure "Picklips," although that never made it intoprint. Events have not let up since.
Medicare's diagnosis-related group (DRG) reimbursement systemwas already in place when SCAN started, and we have been busytracking the impact of cost containment ever since. The outpatientimaging center industry was in its formative stages. We were ableto catch that wave and ride it into safe harbors.
GE Medical Systems was still an avid advocate of high-field overmid-field MRI in mid-1987. That position was soon modified. TomHess of our staff was kept busy sniffing out GE's not-yet-officialmid-field MR Max systems as they flowed from Japan into the U.S.
Monoclonal antibody imaging agents were waiting in the wings in1987, ready to revitalize a sluggish nuclear medicine market.Some things never change. Nuclear medicine did pick up on itsown, however, with the onset of sophisticated multidetector cameras.
Acuson made a big splash with its premium ultrasound system afew years before SCAN started and was tussling with competitorATL over the use of the term computed sonography in 1987. Bothfirms benefited in the intervening years from strong ultrasoundmarket growth. The major multimodality imaging vendors maneuvered--andare still maneuvering--to get a piece of this action.
Johnson & Johnson's Technicare medical imaging subsidiarywas not quite dead five years ago. Technicare executives and technologyhave since spread throughout an industry partial to recirculatingmanagers. The departed vendor seems almost like a grandparentthat we don't quite remember but feel we know well just the same.
Waldo Hinshaw, now vice president of engineering at Toshiba AmericaMRI, and John P. Heinrich, president and COO of Summit World Trade(see story, page 7), led the last group of Technicare engineers,who closed out the Teslacon MRI project and handed it off to GEin 1987. Companies that sprang from Technicare include Summit,Reality Imaging, Ohio Imaging (now part of Picker) and Trionix.
The most important ideas SCAN has presented over the past fiveyears have come from voices within the industry. A look back atsome of those voices during the first six months of the newsletterprovides a unique view of how much this business has changed andhow much it has stayed the same:
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.